NBE-Therapeutics is a privately owned Swiss, Basel-based Biotech company that was founded in 2012 with the vision to develop next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.
- London, 2019-03-05 - NBE-Therapeutics will present at the 9th World ADC Congress Europe in London
- San Diego, USA, 2019-03-04 - NBE-Therapeutics invited to present at Terrapinn's Americas Antibody Congress
- Basel, 2019-01-29 - Unites States Patent and Trademark Office grants US patent on NBE's linker-toxin technology